Mechanism of Action

Not all IL-17A antagonists are the same1

Taltz is different1

Taltz® (ixekizumab)

Binding affinity for IL-17A2
KD 1.8 pM
Structure: Humanized IgG4 monoclonal antibody3

Cosentyx® (secukinumab)

Binding affinity for IL-17A2
KD 100 pM-200 pM
Structure: Human IgG1 monoclonal antibody3

The lower the KD

The higher the binding affinity

*The relationship between the mechanism of action and clinical outcomes has not been determined. Differences in clinical pharmacology cannot be used to establish differences in efficacy or safety.

Cosentyx® is a registered trademark of Novartis AG Corporation.

IL-17A=interleukin-17A; IgG4=immunoglobulin G4; pM=picomolar; IgG1=immunoglobulin G1; KD=dissociation constant.

References: 1. Taltz [package insert]. Indianapolis, IN: Lilly USA, LLC. 2. Paul C. Ixekizumab or secukinumab in psoriasis: what difference does it make? Br J Dermatol. 2018;178:1003‐1005. 3. Kirkham BW, Kavanaugh A, Reich K. Interleukin-17A: a unique pathway in immune-mediated diseases: psoriasis, psoriatic arthritis and rheumatoid arthritis. Immunology. 2014;141:133-142.